| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities | ||||||||
Net loss | ||||||||
-1,826 | -3,911 | -1,696 | -1,267 | -829 | -584 | -620 | -763 | -527 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation expense | ||||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Research and development-acquired license, expensed | ||||||||
39 | 25 | 50 | 10 | 10 | 0 | 0 | 0 | 132 |
Stock issued for research and development | ||||||||
- | - | - | - | - | 0 | 12 | 12 | 11 |
Stock-based compensation | ||||||||
23 | 1,998 | 206 | 87 | 202 | 4 | 5 | 117 | 15 |
Realized gain on marketable securities | ||||||||
4 | - | - | - | - | - | - | - | - |
Unrealized loss on marketable securities | ||||||||
-17 | - | - | - | - | - | - | - | - |
Changes in assets and liabilities: | ||||||||
Prepaid expenses | ||||||||
-53 | -3 | 12 | 13 | 75 | -7 | -7 | 12 | 15 |
Accounts payable | ||||||||
113 | 384 | -181 | 136 | -71 | 116 | -103 | 49 | 31 |
Net cash used in operating activities | ||||||||
-1,582 | -1,499 | -1,637 | -1,046 | -763 | -455 | -697 | -597 | -352 |
Cash flows from investing activities | ||||||||
Purchase of investments | ||||||||
-250 | - | - | - | - | - | - | - | - |
Purchase of research and development licenses | ||||||||
39 | 25 | 50 | 10 | 10 | - | - | - | - |
Sale of marketable securities | ||||||||
300 | - | - | - | - | - | - | - | - |
Net cash provided by (used in) investing activities | ||||||||
10 | -25 | -850 | -10 | -10 | - | - | - | - |
Cash flows from financing activities | ||||||||
Proceeds from issuance of Series A Convertible Preferred Stock and warrants for cash in an offering, net | ||||||||
- | - | - | - | - | 0 | -0 | 0 | 1,186 |
Proceeds from issuance of common stock in the IPO, net of offering cost | ||||||||
- | 0 | -0 | -17 | 5,857 | - | - | - | - |
Proceeds from issuance common stock and warrants, net of offering cost | ||||||||
4,193 | - | - | - | - | - | - | - | - |
Proceeds from exercise of warrants | ||||||||
37 | - | - | - | - | - | - | - | - |
Net cash provided by financing activities | ||||||||
4,231 | 0 | 1,610 | -17 | 5,857 | 0 | -31 | 0 | 1,186 |
Net increase (decrease) in cash | ||||||||
2,658 | -1,524 | -877 | -1,073 | 5,083 | -455 | -729 | -597 | 833 |
Non-cash investing and financing activities | ||||||||
Conversion of preferred stock to common stock upon completion of the IPO | ||||||||
- | 0 | 0 | 0 | 0 | - | - | - | - |
Common stock issued for acquired license | ||||||||
- | - | - | - | - | 0 | 0 | 0 | 132 |
Offering cost included in accrued expenses | ||||||||
- | - | - | - | 17 | - | - | - | - |
Cancellation and retirement of common stock | ||||||||
0 | - | - | - | - | - | - | - | - |